Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy - Trial NCT06317558
Access comprehensive clinical trial information for NCT06317558 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 4000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
N/A
Mar 01, 2024
Dec 31, 2027
Primary Outcome
Pathological Complete Response (pCR),Disease-free survival(DFS)
Summary
The goal of this observational study is to evaluate the efficacy and long-term clinical
 outcomes of different neoadjuvant immunotherapies in NSCLC patients using the real-world
 data. The main questions it aims to answer are:
 
 - What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment?
 
 - How to determine the subgroups of patients benefit from neoadjuvant immunotherapy?
 Participants will receive neoadjuvant immunotherapy the study will analyze the
 real-world data.
Data Source
ClinicalTrials.gov
NCT06317558
Non-Device Trial